Dendreon’s Reached Orbit… Now Who’s Next?
Investment U (November 6th, 2009) Writes:
Dendreon’s Reached Orbit… Now Who’s Next?
by Robert Williams, Publisher
When the opening bell rang on Tuesday morning, as the broader market sagged, shares of Dendreon Corp. (Nasdaq: DNDN) sprinted out of the gates, rising by 5.7%.
Unless you live in a cave, you should know about this biotech stock.
Back in April, shares went “parabolic,” blasting 454% higher during the month.
(That’s not a typo. The stock increased almost five-fold over the course of a single month, rendering the S&P 500’s 10% gain over the same period completely insignificant.)
With an impressive move like that, you might think the run is over. But shares will likely head higher still…
You see, Dendreon is blazing a brand new path in biotech. Its prostate cancer drug, Provenge, which it just submitted to the FDA for approval, is the first
...active immunotherapy, cancer, Contrarian Perspectives, Dendreon Corp., Fda, Immunotherapy, Investing Lessons, InvestmentU, Louis Basenese, player, Prostate Cancer, Provenge;, radiation treatment, RNCOS Inc., Robert Williams;, small and micro-cap specialist, Sp 500, surgery, Vaccines


![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/gold/t24_au_en_usoz_2.gif)
![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/silver/t24_ag_en_usoz_2.gif)






